Search Result

Results for "

PD

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (228) 5-HT Receptor (5) Acyltransferase (4) Adenosine Receptor (6) Adrenergic Receptor (4) Akt (9) Angiotensin Receptor (7) Angiotensin-converting Enzyme (ACE) (2) Antibiotic (20) Antifolate (1) Apoptosis (41) Aryl Hydrocarbon Receptor (4) AUTACs (1) Autophagy (20) Bacterial (20) Bcr-Abl (7) BCRP (1) Beta-secretase (1) Biochemical Assay Reagents (11) Bombesin Receptor (2) c-Fms (2) c-Kit (3) c-Met/HGFR (1) c-Myc (1) Calcium Channel (10) Casein Kinase (3) Caspase (2) CD19 (1) CD28 (1) CD38 (1) CD47 (1) CD73 (1) CDK (11) Checkpoint Kinase (Chk) (2) Cholecystokinin Receptor (8) Cholinesterase (ChE) (8) Complement System (1) COMT (3) COX (4) CTLA-4 (5) Cytochrome P450 (4) Dengue virus (1) Deubiquitinase (1) DGK (6) Dihydrofolate reductase (DHFR) (1) Dipeptidyl Peptidase (1) Discoidin Domain Receptor (2) DNA/RNA Synthesis (3) Dopamine Receptor (29) Drug Intermediate (1) Drug Metabolite (3) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (3) EGFR (17) Endogenous Metabolite (18) Endothelin Receptor (6) Enterovirus (1) ERK (3) Eukaryotic Initiation Factor (eIF) (1) Factor Xa (2) FAK (2) FAP (1) Ferroptosis (1) FGFR (4) FLT3 (2) Fluorescent Dye (2) Fungal (4) GABA Receptor (4) GCGR (1) Glycosidase (3) GPR55 (1) GPR84 (1) GSK-3 (1) HBV (4) HDAC (8) HIF/HIF Prolyl-Hydroxylase (8) Histone Demethylase (3) Histone Methyltransferase (1) HIV Protease (1) HSP (3) IFNAR (2) iGluR (6) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (1) Integrin (1) Interleukin Related (4) Isotope-Labeled Compounds (18) JNK (3) Keap1-Nrf2 (4) LAG-3 (3) Ligands for E3 Ligase (2) Ligands for Target Protein for PROTAC (6) Liposome (1) Lipoxygenase (1) LPL Receptor (1) LRRK2 (5) mAChR (2) MAP4K (5) MEK (12) Melatonin Receptor (1) mGluR (3) Microtubule/Tubulin (1) Mitochondrial Metabolism (2) Mitophagy (4) MMP (2) MNK (3) Monoamine Oxidase (19) mTOR (1) NAMPT (1) Neurotensin Receptor (1) NF-κB (3) NO Synthase (2) NOD-like Receptor (NLR) (1) Opioid Receptor (3) Orexin Receptor (OX Receptor) (1) Orthopoxvirus (4) P-glycoprotein (1) p38 MAPK (3) Parasite (1) PARP (9) PDGFR (2) PDI (1) PGE synthase (2) Phosphatase (2) Phosphodiesterase (PDE) (4) Phospholipase (1) PI3K (4) Potassium Channel (2) Prostaglandin Receptor (3) PROTAC Linkers (3) PROTACs (7) Protease Activated Receptor (PAR) (2) Proteasome (3) Pyroptosis (1) Radionuclide-Drug Conjugates (RDCs) (2) Reactive Oxygen Species (11) Renin (5) ROR (1) SARS-CoV (1) Sialyltransferase (1) Sigma Receptor (3) Small Interfering RNA (siRNA) (2) Sodium Channel (1) Src (6) STAT (6) STING (3) TAM Receptor (1) Target Protein Ligand-Linker Conjugates (2) Tau Protein (1) TGF-β Receptor (2) Thrombin (1) Thyroid Hormone Receptor (2) TNF Receptor (3) Toll-like Receptor (TLR) (6) Topoisomerase (9) Trk Receptor (2) ULK (1) VEGFR (5) Virus Protease (1) Wee1 (4) α-synuclein (20) γ-secretase (2)
By Research Areas:	Cancer (377) Cardiovascular Disease (39) Endocrinology (11) Infection (44) Inflammation/Immunology (109) Metabolic Disease (22) Neurological Disease (165)
Click Chemistry:	DBCO (1) Azide (1) Alkynes (3)
Oligonucleotides:	Pre-designed siRNA Sets (2) siRNAs (2)

680

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: PD-1/PD-L1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .

HY-155959

PD-1/PD-L1-IN-33	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-33 (Compound N11) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC₅₀: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity .

HY-120455

PD 125967	Renin	Cardiovascular Disease Metabolic Disease
PD 125967 is an oligopeptide renin inhibitor. PD 125967 can be used to low blood pressure .

HY-103407A

PD 168568 dihydrochloride	Dopamine Receptor	Neurological Disease Cancer
PD 168568 dihydrochloride is a orally active and potent dopamine receptor D₄ (DRD₄) antagonist. PD 168568 dihydrochloride contains an isoindolinone and is selective for the D₄ receptor versus D₂ and D₃, with K_i values of 8.8, 1842, and 2682 nM, respectively. PD 168568 dihydrochloride can be used for glioblastoma (GBM) research .

HY-103048

PD-1/PD-L1-IN 3	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .

HY-130625

PD-1/PD-L1-IN 6	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN 6 (compound A13) is a potent *PD-1/PD-L1* interaction inhibitor, with an IC₅₀ of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model .

HY-144447

PD-1/PD-L1-IN-17	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-17 (Compound P20) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 26.8 nM. PD-1/PD-L1-IN-17 is a promising lead compound for the development of inhibitors of the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-17 has the potential for the research of cancer diseases .

HY-145770

PD-1/PD-L1-IN-19	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-19 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-19 blocks PD-1/PD-L1 with the IC₅₀ of 62.3 nM. PD-1/PD-L1-IN-19 can be used for the research of cancers, infectious diseases and autoimmune diseases .

HY-145771

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases .

HY-157811

PD-1/PD-L1-IN-40	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-40 (Compound EP16) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-40 inhibits the generation of exosomal PD-L1 with IC₅₀ = 0.108 μM. PD-1/PD-L1-IN-40 can serve as a leading compound for exosomal PD-L1 abrogation. PD-1/PD-L1-IN-40 can be used for the research of cancer .

HY-144258

PD-1/PD-L1-IN-14	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of *PD-1/PD-L1* interactions, with an IC₅₀ of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 .

HY-152240

PD-1/PD-L1-IN-29	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 (S4-1) is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity .

HY-145772

PD-1/PD-L1-IN-21	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-21 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-21 blocks PD-1/PD-L1 with the IC₅₀ of 4.99 μM. PD-1/PD-L1-IN-21 can be used for the research of cancers, infectious diseases and autoimmune diseases .

HY-145773

PD-1/PD-L1-IN-22	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-22 (Example 2) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-22 blocks PD-1/PD-L1 with the IC₅₀ of 0.732 μM. PD-1/PD-L1-IN-22 can be used for the research of cancers, infectious diseases and autoimmune diseases .

HY-159892

PD-1/PD-L1-IN-54	PD-1/PD-L1 IFNAR Interleukin Related PI3K Akt	Cancer
PD-1/PD-L1-IN-54 (Compound 6) is a moderately affinic *PD-1/PD-L1* inhibitor (K_D: PD-1, 55.8 μM; PD-L1, 46.4 μM; IC₅₀: 88.6 μM). PD-1/PD-L1-IN-54 inhibits PD-1/PD-L1 interactions and shows anticancer activity by activating CD8 ⁺ T cells, upregulating PD-1 expression, and increasing secretion of IFN-γ and IL-2. PD-1/PD-L1-IN-54 inhibits cancer cell proliferation and promotes apoptosis. PD-1/PD-L1-IN-54 also regulates T cell immunity through the PI3K/Akt pathway correlated with PD-1/PD-L1 .

HY-145768

PD-1/PD-L1-IN-18	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-18 (Compound L31) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-18 blocks PD-1/PD-L1 with the IC₅₀ of 1.054 μM. Antitumor Activity .

HY-129172A

PD-1/PD-L1-IN 5	PD-1/PD-L1	Infection Inflammation/Immunology Cancer
PD-1/PD-L1-IN 5 is a *PD-1/PD-L1* protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC₅₀ of ≤100 nM .

HY-168080

PD-1/PD-L1-IN-51	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-51 (Compound III-4) is a *PD-1/PD-L1* inhibitor (IC₅₀: 2.9 nM for hPD-L1). PD-1/PD-L1-IN-51 directly binds to PD-L1 to block the interaction between PD-1/PD-L1 and enhances IFN-γ release. PD-1/PD-L1-IN-51 has tumor inhibitory activity .

HY-163534

PD-1/PD-L1-IN-43	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-43 (compound Z13) is a small-molecule inhibitors targeting the *PD-1/PD-L1* interaction. PD-1/PD-L1-IN-43 exhibites potent in vivo antitumor efficacy against B16-F10 melanoma. PD-1/PD-L1-IN-43 inhibits tumor growth by blocking the interaction between *PD-1* and *PD-L1*. PD-1/PD-L1-IN-43 can be used in anti-tumor studies .

HY-143305

PD-1/PD-L1-IN-25	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of *PD-1/PD-L1* interaction with an IC₅₀ value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer .

HY-N12537

PD-1/PD-L1-IN-38	PD-1/PD-L1	Cancer
PD-1/ PD-L1-in-38 is a *PD-1/PD-L1* inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 ⁺ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity .

HY-163041

PD-1/PD-L1-IN-36	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-36 (Compound 2k) is a *PD-1/PD-L1* complex inhibitor (IC₅₀: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy .

HY-160585

PD-L1/PD-1-IN-1	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-L1/PD-1-IN-1 (compound 8j) is a potent inhibitor of *PD-L1/PD* interaction, with IC₅₀ ＜ 1 nM. PD-L1/PD-1-IN-1 plays an important role in anti-tumor research .

HY-163307

PD-1/PD-L1-IN-39	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-39 (X 14) is an orally active *PD-1/PD-L1* inhibitor with a IC₅₀ value of 15.73 nM. PD-1/ PD-L1-in-39 has a good binding affinity for human and mouse PD-L1, with K_D values of 14.62 nM and 392 nM, respectively. PD-1/PD-L1-IN-39 has antitumor activity .

HY-146740

PD-1/PD-L1-IN-27	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-27 is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8 ⁺ T cells and reduces T cell exhaustion .

HY-144649

PD-1/PD-L1-IN-24	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-24 is a highly potent *PD-1/PD-L1* inhibitor with IC₅₀ value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs .

HY-144442

PD-1/PD-L1-IN-15	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-15 (Compound M17) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 60.1 nM. PD-1/PD-L1-IN-15 has the potential for the research of tumor immunoresearch .

HY-144443

PD-1/PD-L1-IN-16	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-16 (Compound M23) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ value of 53.2 nM. PD-1/PD-L1-IN-16 has the potential for the research of tumor immunoresearch .

HY-163837

PD-1/PD-L1-IN-48	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-48 (compound HD10) is a potent inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.1 nM. PD-1/PD-L1-IN-48 plays an important role in cancer research .

HY-169190

PD-1/PD-L1-IN-53	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-53 (compound B3) is an inhibitor targeting *PD-1/PD-L1* and VISTA signaling pathways. PD-1/PD-L1-IN-53 can be used in anti-cancer research .

HY-129172

PD-1/PD-L1-IN 5 TFA	PD-1/PD-L1	Infection Inflammation/Immunology Cancer
PD-1/PD-L1-IN 5 TFA is a *PD-1/PD-L1* protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC₅₀ of ≤100 nM .

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC₅₀ of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy .

HY-145774

PD-1/PD-L1-IN-23	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of *PD-1/PD-L1*. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice .

HY-168081

PD-1/PD-L1-IN-52	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-52 (Compound III-5) is an orally active *PD-1/PD-L1* inhibitor that blocks the interaction between PD-1 and PD-L1, with an IC₅₀ of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% .

HY-162343

PD-1/PD-L1-IN-41	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/ PD-L1-in-41 (Compound 5c) is a *PD-L1* and *PD-1* inhibitor with IC₅₀ value of 10.2 nM .

HY-132192

PD-1/PD-L1-IN-9 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model .

HY-144746

PD-1/PD-L1-IN-26	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-26 (Compound II-14) is a potent inhibitor of *PD-1/PD-L1* with an IC₅₀ of 0.0380 μM. PD-1/PD-L1-IN-26 activates the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues. PD-1/PD-L1-IN-26 has the potential for the research of cancer diseases .

HY-132192A

PD-1/PD-L1-IN-9 hydrochloride 1 Publications Verification	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of *PD-1/PD-L1* interaction, with an IC₅₀ of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model .

HY-129695

PD 132002	Renin	Cardiovascular Disease
PD 132002 is an orally active, potent renin inhibitor. PD 132002 weakly inhibits pepsin. PD 132002 produces substantial reductions in blood pressure .

HY-124229

PD 122860	Sodium Channel Calcium Channel	Cardiovascular Disease
PD 122860 is a calcium channel blocker. PD 122860 also can stimulate sodium channel. PD 122860 can be used for the research of cardiovascular and cerebrovascular diseases .

HY-161713

PD-1/PD-L1-IN-45	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-45 (Compound 2) is an inhibitor for PD-1/PD-L1 Interaction with EC₅₀ of 21.8 nM .

HY-159125

PD-1/PD-L1-IN-47	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-47 (MolPort-001-742-690) is a PH-selective *PD-1/PD-L1* signaling pathway inhibitor with significant affinity for PD-L1 under acidic conditions and lower toxicity. PD-1/PD-L1-IN-47 can be used in the study of tumors .

HY-148305

PD-1/PD-L1-IN-28	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-28 (compound 3) is an immune checkpoint inhibitor of *PD-1/PD-L1* signaling pathway (IC₅₀=0.744 µM). PD-1/PD-L1-IN-28 shows good research potential in tumor immunity .

HY-168078

PD-1/PD-L1-IN-50	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-50 (Compound LG-12) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-50 increases the secretion of IFN-γ to promote CD8 + T cell activation, and activates the antitumor immunity of T cells .

HY-131347

PD-1/PD-L1-IN-NP19	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-NP19 is a *PD-1/PD-L1* inhibitor, with an IC₅₀ of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects .

HY-149356

PD-1/PD-L1-IN-31	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC₅₀=2.2 nM). PD-1/PD-L1-IN-31 promotes secretion of the IFN-γ, and induces immune activity of peripheral blood mononuclear cells (PBMCs) to inhibits tumor cells .

HY-161518

PD-1/PD-L1-IN-44	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-44 (Compound 22) selectively inhibits *PD-1/PD-L1* proteins (IC₅₀=1.21 nM). PD-1/PD-L1-IN-44 inhibits tumor growth without toxicity in animal models and increases CD8 ⁺ cell infiltration .

HY-161748

PD-1/PD-L1-IN-46	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-46 (compound (R)-C27 ) is an PD-1/PD-L1 antagonist with IC₅₀ value of 18.66 nM .

HY-132202

PD-1/PD-L1-IN-10	PD-1/PD-L1 Apoptosis	Cancer
PD-1/PD-L1-IN-10 (compound B2) is an orally active *PD-1/PD-L1* inhibitor (IC₅₀ of 2.7 nM) with potent anticancer efficacy .

HY-114547R

PD 109488 (Standard)	Others	Others
PD 109488 (Standard) is the analytical standard of PD 109488. This product is intended for research and analytical applications. PD 109488 is a quinapril diketopiperazine metabolite .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0502

Enrofloxacin Maximum Cited Publications 10 Publications Verification BAY Vp 2674; PD160788	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Bacterial Antibiotic Endogenous Metabolite Orthopoxvirus
Enrofloxacin (BAY Vp 2674) is an effective antibiotic with an MIC₉₀ of 0.312 μg/mL for Mycoplasma bovis.

HY-B0502A

Enrofloxacin monohydrochloride Maximum Cited Publications 10 Publications Verification BAY Vp 2674 monohydrochloride; PD160788 monohydrochloride	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Bacterial Antibiotic Endogenous Metabolite Orthopoxvirus
Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) is an effective antibiotic with an MIC₉₀ of 0.312 μg/mL for Mycoplasma bovis. Enrofloxacin monohydrochloride shows inhibitory activity against vaccinia virus (VV).

HY-125863

Glucose-6-phosphate dehydrogenase, Microorganism G6PD	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
Glucose-6-phosphate dehydrogenase, Microorganism (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase, Microorganism is a primary source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 systems, and others. Glucose-6-phosphate dehydrogenase, Microorganism is applicable in research related to diabetes, endothelial dysfunction, cancer, and cardiomyopathy .

HY-N0460

1-Caffeoylquinic acid 1 Publications Verification	Phyllodium pulchellum (L.) Desv. Classification of Application Fields Source classification Phenols Polyphenols Plants Compositae Disease Research Fields Cancer	NF-κB
1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with K_i of 0.002 μM and binding energy of 1.50 Kcal/mol . 1-Caffeoylquinic acid has anti-oxidative stress ability . 1-Caffeoylquinic acid inhibits *PD-1/PD-L1* interact .

HY-113366

Prostaglandin J2 PGJ2	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Prostaglandin Receptor Endogenous Metabolite
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with K_is of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC₅₀ value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD) .

HY-N0242

Fraxinellone 3 Publications Verification	Structural Classification Classification of Application Fields Terpenoids Dictamnus dasycarpus Turcz. Sesquiterpenes Source classification Rutaceae Plants Inflammation/Immunology Disease Research Fields	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT
Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a *PD-L1* inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1 .

HY-N12537

PD-1/PD-L1-IN-38	Structural Classification Ketones, Aldehydes, Acids Labiatae Source classification Samanea saman (Jacq.) Merr. Plants	PD-1/PD-L1
PD-1/ PD-L1-in-38 is a *PD-1/PD-L1* inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 ⁺ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity .

HY-N12537A

(2R,3S)-PD-1/PD-L1-IN-38	Structural Classification Ketones, Aldehydes, Acids Labiatae Source classification Samanea saman (Jacq.) Merr. Plants	Aryl Hydrocarbon Receptor PD-1/PD-L1
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8 ⁺T cells and inhibits the signal transduction of PD-1/PD-L1 .

HY-121252

Dopal	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Endogenous Metabolite Reactive Oxygen Species α-synuclein
Dopal is an aldehyde that can be generated in Parkinson's disease by enzymatic degradation of dopamine. Dopal can generate reactive oxygen species, and triggers aggregation of α-synuclein. DOPAL elicits α-synuclein accumulation and hampers α-synuclein clearance in primary neurons .

HY-N0460R

1-Caffeoylquinic acid (Standard)	Phyllodium pulchellum (L.) Desv. Structural Classification Source classification Phenols Polyphenols Plants Compositae	NF-κB
1-Caffeoylquinic acid (Standard) is the analytical standard of 1-Caffeoylquinic acid. This product is intended for research and analytical applications. 1-Caffeoylquinic acid is an effective NF-κB inhibitor, shows significant binding affinity to the RH domain of p105 with Ki of 0.002 μM and binding energy of 1.50 Kcal/mol . 1-Caffeoylquinic acid has anti-oxidative stress ability . 1-Caffeoylquinic acid inhibits PD-1/PD-L1 interact .

HY-N2526

Nervonic acid 3 Publications Verification Selacholeic acid; cis-15-Tetracosenoic acid	Structural Classification Microorganisms other families Ketones, Aldehydes, Acids Source classification Disease markers Endocrine diseases Plants Endogenous metabolite	Endogenous Metabolite NF-κB
Nervonic acid is a monounsaturated fatty acid with oral activity. Nervonic acid exerts anti-inflammatory activity by inhibiting NF-κB signaling. Nervonic acid can be used in the study of neurodegenerative diseases .

HY-N0242R

Fraxinellone (Standard)	Structural Classification Terpenoids Dictamnus dasycarpus Turcz. Sesquiterpenes Source classification Rutaceae Plants	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT
Fraxinellone (Standard) is the analytical standard of Fraxinellone. This product is intended for research and analytical applications. Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1 .

HY-N0079

Praeruptorin C	Cardiovascular Disease Chrysanthemum × morifolium (Ramat.) Hemsl. Classification of Application Fields Source classification Coumarins Phenylpropanoids Plants Umbelliferae Disease Research Fields	Calcium Channel
Praeruptorin C is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin C is a calcium antagonist with pD₂ ^′ value of 5.7 .

HY-N6066

Praeruptorin E	Cardiovascular Disease Structural Classification Classification of Application Fields Source classification Coumarins Salvia hypargeia Fisch. & C.A.Mey. Phenylpropanoids Umbelliferae Plants Disease Research Fields	Calcium Channel
Praeruptorin E is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin C is a calcium antagonist with pD₂ ^′ value of 5.2 .

HY-150058

Bocconoline	Alkaloids Source classification Bocconia pearcei Plants Isoquinoline Alkaloids Papaveraceae	Others
Bocconoline is a potent early endosome antigen 1 (EEA1) inhibitor. Bocconoline can be isolated from Macleaya cordata. Bocconoline can be used for the research of Parkinson’s disease (PD) .

HY-16468

Squalamine MSI-1256	Infection Triterpenes Structural Classification Animals Classification of Application Fields Terpenoids Marine natural products Other marine organisms Disease Research Fields Cancer	Bacterial HBV FAK Dengue virus
Squalamine (MSI-1256) is an aminosterol compound with broad-spectrum antiviral activity. Squalamine makes cells less conducive to certain viral replication by altering the electrostatic interactions in the inner membrane of host cells. Squalamine also has antibacterial and antitumor activities. Squalamine has broad-spectrum antibacterial activity against Gram-negative and Gram-positive bacteria, fungi and protozoa. Squalamine inhibits tumor-related angiogenesis and the growth of human breast cancer cells. Squalamine restores the function of enteric nervous system in Parkinson ^,s disease mouse models .

HY-W342604

N-Acetylputrescine NAP	Structural Classification Alkaloids Human Gut Microbiota Metabolites Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
N-Acetylputrescine (NAP) is an endogenous metabolite widely present in animals and plants. N-Acetylputrescine can be used as a biomarker for lung squamous cell carcinoma (SCCL) and Parkinson's disease (PD) for disease diagnosis .

HY-162614

Rogersonin E	Structural Classification Natural Products Microorganisms Source classification	PD-1/PD-L1
Rogersonin E can be isolated from an Ophiocordyceps-associated fungus, Clonostachys rogersoniana. Rogersonin E downregulates the expression of *PD-L1* protein in MDA-MB-231 and A549 cells .

HY-N0120A

Polydatin Maximum Cited Publications 10 Publications Verification Piceid	Structural Classification Classification of Application Fields Anti-aging Polygonaceae Reynoutria japonica Houtt. Source classification Plants Stilbenes Phenols Polyphenols Inflammation/Immunology Disease Research Fields Cancer	Autophagy Apoptosis Mitophagy
Polydatin (Piceid), extracted from the roots of Reynoutria japonica, a widely used traditional Chinese remedies, possesses anti-inflammatory activity in several experimental models. Polydatin (Piceid) inhibits G6PD and induces oxidative and ER stresses.

HY-121152

Chiisanoside	Eleutherococcus henryi var. faberi (Harms) S. Y. Hu Triterpenes Structural Classification Terpenoids Source classification Plants Araliaceae	α-synuclein Apoptosis GABA Receptor Dopamine Receptor
Chiisanoside exhibits neuroprotective, anticancer, antidepressant, anti-inflammatory, anti-obesity and anti-platelet activities. Chiisanoside inhibits tumor growth in H22 xenograft mouse model, through immunoregulation, induction of apoptosis and inhibition of angiogenesis. Chiisanoside attenuates Parkinson’s disease through regulation of Parkin/ZNF746/PGC-1α axis, and promotion of mitochondrial biogenesis .

HY-N15190

Sesaminol	Structural Classification Acanthaceae Source classification Lignans Justicia procumbens Linnaeus Phenylpropanoids Plants	Keap1-Nrf2 Reactive Oxygen Species
Sesaminol is an orally active activator for Nrf2-ARE pathway, that promotes the the nuclear translocation of Nrf2 and enhances the NQO1 expression, thereby enhances the cell's defense against oxidative stress. Sesaminol inhibits 6-OHDA (HY-B1081)-induced ROS production and apoptosis in cell SH-SY5Y. Sesaminol exhibits neuroprotective efficacy against Rotenone (HY-B1756)-induced Parkinson's disease .

HY-N6066R

Praeruptorin E (Standard)	Structural Classification Source classification Coumarins Salvia hypargeia Fisch. & C.A.Mey. Phenylpropanoids Umbelliferae Plants	Calcium Channel
Praeruptorin E (Standard) is the analytical standard of Praeruptorin E. This product is intended for research and analytical applications. Praeruptorin E is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin C is a calcium antagonist with pD2′ value of 5.2 .

HY-N0120AR

Polydatin (Standard) Maximum Cited Publications 10 Publications Verification Piceid (Standard)	Structural Classification Stilbenes Classification of Application Fields Anti-aging Polygonaceae Reynoutria japonica Houtt. Source classification Phenols Plants Inflammation/Immunology Disease Research Fields Cancer	Autophagy Apoptosis Mitophagy
Polydatin (Standard) is the analytical standard of Polydatin. This product is intended for research and analytical applications. Polydatin (Piceid), extracted from the roots of Reynoutria japonica, a widely used traditional Chinese remedies, possesses anti-inflammatory activity in several experimental models. Polydatin (Piceid) inhibits G6PD and induces oxidative and ER stresses.

HY-121259

Doxorubicinol Adriamycinol; DXR-OL	Cardiovascular Disease Quinones Structural Classification Classification of Application Fields Anthraquinones Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Doxorubicinol, a potent inhibitor of the cardiac sarcoplasmic reticulum calcium pump, inhibits systolic myocardial function in isolated heart muscle. Doxorubicinol inhibits tumor cell growth and has cardiotoxicity.

HY-N0596

Panaxadiol 20(R)-Panaxadiol	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Araliaceae Cancer	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT
Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities .

HY-N0596R

Panaxadiol (Standard)	Panax ginseng C. A. Meyer Triterpenes Structural Classification Terpenoids Source classification Plants Araliaceae	PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT
Panaxadiol (Standard) is the analytical standard of Panaxadiol. This product is intended for research and analytical applications. Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities .

HY-N3005

Britannin 1 Publications Verification	Phyllodium pulchellum (L.) Desv. Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Compositae Inflammation/Immunology Disease Research Fields	Apoptosis Autophagy NOD-like Receptor (NLR) Pyroptosis
Britannin is an NLRP3 inhibitor with an IC₅₀ of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the NLRP3 inflammasome by blocking the interaction between NLRP3 and NEK7. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics .

HY-B2167R

Docosahexaenoic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Disease markers Endogenous metabolite Cardiovascular System Disorder	Endogenous Metabolite
Docosahexaenoic acid (Standard) is the analytical standard of Docosahexaenoic acid. This product is intended for research and analytical applications. Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk. In Vitro: Docosahexaenoic acid (DHA) is essential for the growth and functional development of the brain in infants. DHA is also required for maintenance of normal brain function in adults. The inclusion of plentiful DHA in the diet improves learning ability and memory . DHA is an essential requirement in every step of brain development like neural cell proliferation, migration, differentiation, synaptogenesis. The multiple double bonds and unique structure allow DHA to impart special membrane characteristics for effective cell signaling. Many development disorders like dyslexia, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia etc. are causally related to decreased level of DHA . DHA is a potent RXR ligand inducing robust RXR activation already at low micro molar concentrations. The EC₅₀ for RXRα activation by DHA is about 5-10 μM fatty acid . In Vivo: Docosahexaenoic acid administration over 10 weeks significantly reduces the number of reference memory errors, without affecting the number of working memory errors, and significantly increases the docosahexaenoic acid content and the docosahexaenoic acid/arachidonic acid ratio in both the hippocampus and the cerebral cortex . DHA treatment exerts neuroprotective actions on an experimental mouse model of PD. There is a decrease tendency in brain lipid oxidation of MPTP mice but it does not significantly .

Cat. No.	Product Name	Chemical Structure

HY-50767S

Palbociclib-d8
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-B0502S

Enrofloxacin-d5
Enrofloxacin-d₅ is the deuterium labeled Enrofloxacin. Enrofloxacin (BAY Vp 2674) is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.

HY-132559S

PD-166285-d4
PD-166285-d₄ is the deuterium labeled PD-166285[1].

HY-100937S

DPCPX-d4
DPCPX-d₄ (PD 116948-d₄) is deuterium-labeled DPCPX (HY-100937) .

HY-10581AS1

Gatifloxacin-d4 hydrochloride
Gatifloxacin-d₄ (AM-1155-d₄; BMS-206584-d₄; PD135432-d₄) hydrochloride is deuterium-labeled Gatifloxacin (hydrochloride) (HY-10581A) .

HY-50767S1

Palbociclib-d4 hydrochloride
Palbociclib-d₄ (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-W654305

Palbociclib-d4

Palbociclib-d₄ is deuterium labeled Palbociclib. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-10581AS

Gatifloxacin-d3 hydrochloride

Gatifloxacin-d₃ (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

HY-B0502AS

Enrofloxacin-d5 hydrochloride
Enrofloxacin-d₅ (hydrochloride) is deuterium labeled Enrofloxacin (monohydrochloride). Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.

HY-B0502AS1

Enrofloxacin-d5 hydriodide
Enrofloxacin-d₅ (hydriodide) is the deuterium labeled Enrofloxacin (monohydrochloride). Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.

HY-W700069

Gatifloxacin-d4
Gatifloxacin-d4 is the deuterium labeled Gatifloxacin .

HY-165645

Protectin D1-d5
Protectin D1-d₅ (Neuopotecti D1-d₅) is deuterium labeled Protectin D1 .

HY-121246S

Fluorofenidone-d3
Fluorofenidone-d₃ is deuterium labeled Fluorofenidone. Fluorofenidone (AKF-PD), an analogue of AMR69, shows equivalent antifibrotic activity, lower toxicity and longer half-life. Fluorofenidone (AKF-PD) attenuates the progression of renal interstitial fibrosis partly by suppressing NADPH oxidase and extracellular matrix (ECM) deposition via the PI3K/Akt signalling pathway[1][2].

HY-W778336

Girard's Reagent P-d5
Girard's Reagent P-d5 is a deuterated labeled Girard's Reagent P-d5 .

HY-W654081

Bisphenol P-d16
Bisphenol P-d₁₆ is deuterium labeled α,α'-Bis(4-hydroxyphenyl)-1,4-diisopropylbenzene .

HY-146836S1

16:0 PI(5)P-d5 ammonium
16:0 PI(5)P-d5 (ammonium) is the deuterium labeled 16:0 PI(5)P (ammonium) .

HY-146836S

(Rac)-16:0 PI(5)P-d5 ammonium
(Rac)-16:0 PI(5)P-d₅ (ammonium) is deuterium labeled (Rac)-16:0 PI(5)P (ammonium).

HY-146836S2

(Rac)-16:0 PI(5)P-d5 diammonium
(Rac)-16:0 PI(5)P-d₅ diammonium is deuterium labeled (Rac)-16:0 PI(5)P diammonium .

HY-17355S

Pramipexole-d7 dihydrochloride

Pramipexole-d₇ (dihydrochloride) is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

HY-17355S1

Pramipexole-d5 dihydrochloride

Pramipexole-d₅ (dihydrochloride) is deuterium labeled Pramipexole (dihydrochloride). Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

HY-B0410S1

Pramipexole-d5
Pramipexole-d₅ is the deuterium labeled Pramipexole[1]. Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[2][3][4].

HY-17355S2

Pramipexole-d7-1 dihydrochloride

Pramipexole-d₇-1 (dihydrochloride) is the deuterium labeled Pramipexole dihydrochloride[1]. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[2][3][4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks